Last reviewed · How we verify

Articaine Hydrochloride + Epinephrine

Ankara Yildirim Beyazıt University · FDA-approved active Small molecule

Articaine is a local anesthetic that blocks sodium channels in nerve membranes, while epinephrine is a vasoconstrictor that prolongs anesthetic duration and reduces bleeding.

Articaine is a local anesthetic that blocks sodium channels in nerve membranes, while epinephrine is a vasoconstrictor that prolongs anesthetic duration and reduces bleeding. Used for Local and regional anesthesia for dental procedures, Infiltration anesthesia for minor surgical procedures.

At a glance

Generic nameArticaine Hydrochloride + Epinephrine
Also known asultracaine ds, local anesthetic
SponsorAnkara Yildirim Beyazıt University
Drug classLocal anesthetic with vasoconstrictor
TargetVoltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
ModalitySmall molecule
Therapeutic areaAnesthesia / Dentistry
PhaseFDA-approved

Mechanism of action

Articaine hydrochloride works by reversibly inhibiting sodium influx into nerve cells, preventing depolarization and action potential propagation. The addition of epinephrine causes vasoconstriction of local blood vessels, which slows systemic absorption of the anesthetic, extends its duration of action, and reduces local bleeding during procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: